Big Health's DaylightRx Receives FDA Clearance for GAD Treatment
![Big Health's DaylightRx Receives FDA Clearance for GAD Treatment](https://investorshangout.com/images/blog/ihnews-Big%20Health%27s%20DaylightRx%20Receives%20FDA%20Clearance%20for%20GAD%20Treatment.jpg)
Big Health Achieves FDA Clearance for DaylightRx
First non-drug FDA-cleared treatment for generalized anxiety disorder (GAD).
Big Health, a prominent developer in digital mental health solutions, has received a significant clearance from the U.S. Food and Drug Administration (FDA) for its innovative digital therapeutic known as DaylightRx. This development marks a notable milestone as DaylightRx becomes the first FDA-approved digital treatment specifically targeting generalized anxiety disorder (GAD). The next step for this digital therapeutic involves making it available through licensed healthcare providers who can prescribe it to eligible patients.
Understanding DaylightRx and Its Importance
DaylightRx utilizes evidence-based techniques from cognitive behavioral therapy (CBT) tailored for individuals dealing with GAD. The therapeutic aims to alleviate chronic worry and anxiety by teaching users practical strategies. The treatment involves interactive lessons that cover applied relaxation techniques, stimulus control to minimize worry frequency, cognitive restructuring to combat anxious thoughts, and exposure exercises to reduce the intensity of worry.
This structured approach, which encompasses guided practice sessions, spans over a 90-day treatment period. Individuals participating in DaylightRx can learn to integrate these strategies into their everyday lives, potentially improving their overall mental well-being.
The Impact of Generalized Anxiety Disorder
Generalized anxiety disorder is characterized by excessive and uncontrollable worry. Patients often face various physical symptoms, which can hinder daily functioning. Statistically, GAD is among the most prevalent anxiety disorders and comes with a staggering economic burden, costing the U.S. economy over $53 billion annually. Moreover, individuals suffering from GAD are at an increased risk for developing other illnesses, including depression, diabetes, heart disease, and hypertension.
Proven Efficacy of DaylightRx
Clinical trials have underscored DaylightRx's effectiveness, demonstrating a remarkable remission rate exceeding 70%. Patients have reported significant reductions in anxiety levels, often sustained for six months or longer following treatment. These promising results provide hope for many who struggle with this chronic condition.
Recent Developments and Future Initiatives
This clearance marks the second FDA-approved product from Big Health within a single year. Previously, their SleepioRx treatment was authorized for insomnia disorder. Furthermore, upcoming changes in healthcare reimbursements, including proposals for the 2025 Medicare Physician Fee Schedule, may facilitate coverage for FDA-cleared digital mental health therapies like DaylightRx and SleepioRx.
By integrating these digital therapeutic solutions into clinical practice, Big Health aims to enhance access to mental health care for individuals across the nation, addressing the pressing demand for effective treatment options.
Message from Big Health's Leadership
Yael Berman, CEO of Big Health, expressed the company’s commitment to expanding non-pharmaceutical treatment alternatives for anxiety. "For too long, patients seeking non-drug treatment options have had limited choices. With our FDA-cleared treatment, we're thrilled to offer an effective alternative that patients can depend on, featuring impressive remission rates of over 70%." This dedication underscores Big Health's mission of providing accessible mental health care solutions for those in need.
About Big Health
Big Health is dedicated to improving mental health on a large scale through the development of digital treatments aimed at common conditions like insomnia, anxiety, and depression. With a base of over 90 research publications and 18 rigorous clinical trials, their programs are designed by leading experts in the field. For over ten years, Big Health has collaborated with employers, health plans, and global health systems to deliver scalable mental health care solutions. To learn more about Big Health's offerings, visit their website.
Frequently Asked Questions
What is DaylightRx?
DaylightRx is an FDA-cleared digital therapeutic designed to treat generalized anxiety disorder using cognitive behavioral therapy techniques.
How does DaylightRx work?
This treatment provides interactive lessons and exercises that focus on techniques to reduce anxiety and improve mental well-being.
What are the benefits of using DaylightRx?
DaylightRx has shown a remission rate of over 70% in clinical trials, significantly reducing anxiety levels for many users.
Who can use DaylightRx?
DaylightRx is intended for patients aged 22 years and older who are struggling with symptoms of generalized anxiety disorder.
What other treatments does Big Health offer?
In addition to DaylightRx, Big Health provides various digital solutions for insomnia, anxiety, and depression, focusing on accessible mental health care.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Inspiring Stories from Shriners Children's Athletes for Paris 2024
- Rescue Village's Woofstock Raises Over $100,000 for Animals
- Biocare Medical and Ensigna Biosystems Form Strategic Alliance
- Challenges Looming for Q3 Earnings Amid Economic Uncertainty
- Google's Compliance Proposals Under EU Scrutiny for Fairness
- Troubling Times for Intel: Stock Continues to Plummet
- Registration Now Open for Inaugural Global Compass Event
- Blueprint Prep Opens $20,000 Medical School Scholarship for 2024
- ABANZA Secures $5 Million in Pre-Series A Funding for Growth
- San Antonio: A Booming Hub for Cybersecurity and Innovation
- AXS LAW Launches Class Action Against Crypto Bank for Fraud
- Elon Musk's X Appeals California's Content Moderation Law
- Announcing Colorado Youth Sports Giving Day for Young Athletes
- Ford Foundation and RIIF Invest in Appalachia's Local Economy
- Exacto Receives Growth Investment from S2G Ventures and Skyline
- ITG Brands Honored with Kathiann Lester Award for Diversity
- Governor Kathy Hochul: Protecting Home Care for All New Yorkers
- Curran Group Enhances Community Engagement for Suicide Prevention
- Pixalate's Q2 2024 Ad Fraud Insights for Mobile Apps
- EHang Addresses Misinformation Impacting Stock Stability
- Halper Sadeh LLC Launches Investigation for Shareholders in ITI, SDIG, DFS
- Halper Sadeh LLC Looks Into FRZA, SPR, and DM for Shareholders
- Halper Sadeh LLC Investigates Securities Violations for SGRP, AGR, SHCR
- SemperVirens Names Henri Cournand as New CFO for Growth
- Laura O'Connor Earns HousingWire Vanguard Honor for 2024 Again
Recent Articles
- Rescue Village's Woofstock Raises Over $100,000 for Animals
- BioMarin Unveils New Strategy and 2027 Financial Projections
- The Inspiring Investor: Anne Scheiber's Remarkable Story
- Surge in Automotive Wire Demand Amid Electric Vehicle Revolution
- Halper Sadeh LLC Investigates Securities Violations for SGRP, AGR, SHCR
- Big Health's DaylightRx Receives FDA Clearance for GAD Treatment
- CarMax Park Unveiled: A New Era for Richmond Flying Squirrels
- Increased Odds for Significant Fed Rate Cut This September
- Understanding Your Net Worth: Class Definitions and Insights
- Electrolyzer Market Expected to Soar to USD 42.4 Billion
- Stéphane Cassagne Joins ARGAN's Executive Board and Portfolio
- Veridian Healthcare Strengthens Portfolio with Zewa Acquisition
- Court Allows Age Discrimination Lawsuit Against Social Media Company
- College of Charleston Unveils Renovated Albert Simons Center
- Empowerment Through Change: The New Knew's Gray Hair Course
- Bybit Web3 Launches Babylon Season with Exciting Opportunities
- Mid-Atlantic BioTherapeutics and Accelero Unite for Drug Discovery
- Hilb Group Expands with Strategic Acquisition in Benefits Sector
- Ivans Index Reveals August 2024 Premium Trends in Insurance
- Cyclacel Pharmaceuticals to Participate in Global Investment Conference
- FAT Brands' Wing Concepts Unveil Exciting Fall Menu Items
- Tropicana and Ciara Miller Celebrate the Beauty of Summer
- Whitney Economics Lowers Hemp Acreage Forecast Significantly
- Acer Unveils TravelMate P6 14 AI: A Game Changer in Laptops
- GUESS Watches Marks 40 Years of Trendsetting Innovation